1026 related items for PubMed ID: 24636168
1. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
Bal AK, Prasad D, Umali Pamintuan MA, Mammen-Prasad E, Petrova A.
Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
[Abstract] [Full Text] [Related]
2. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[Abstract] [Full Text] [Related]
3. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
4. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
Li W, He X, Zhang L, Wang Z, Wang Y, Lin H, Yuan J, Xie X, Qin Y, Huang P.
Cardiovasc Ther; 2021 Apr; 2021():6660407. PubMed ID: 34239607
[Abstract] [Full Text] [Related]
5. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[Abstract] [Full Text] [Related]
6. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
7. Risk factors for coronary artery lesions in children with Kawasaki disease.
Duan J, Jiang H, Lu M.
Arch Argent Pediatr; 2020 Oct; 118(5):327-331. PubMed ID: 32924395
[Abstract] [Full Text] [Related]
8. Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment.
Downie ML, Manlhiot C, Collins TH, Chahal N, Yeung RSM, McCrindle BW.
Int J Cardiol; 2017 Jun 01; 236():157-161. PubMed ID: 28089146
[Abstract] [Full Text] [Related]
9. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
Platt B, Belarski E, Manaloor J, Ofner S, Carroll AE, John CC, Wood JB.
JAMA Netw Open; 2020 Jan 03; 3(1):e1918565. PubMed ID: 31899532
[Abstract] [Full Text] [Related]
10. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
Pediatr Infect Dis J; 2018 Oct 03; 37(10):976-980. PubMed ID: 29461447
[Abstract] [Full Text] [Related]
11. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
[Abstract] [Full Text] [Related]
12. [Risk factors for coronary artery lesions in children with Kawasaki disease].
Li Y, Wang XM, Liu YL, Shi K, Yang YF, Guo YH.
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec 31; 14(12):938-41. PubMed ID: 23234782
[Abstract] [Full Text] [Related]
13. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin.
Kibata T, Suzuki Y, Hasegawa S, Matsushige T, Kusuda T, Hoshide M, Takahashi K, Okada S, Wakiguchi H, Moriwake T, Uchida M, Ohbuchi N, Iwai T, Hasegawa M, Ichihara K, Yashiro M, Makino N, Nakamura Y, Ohga S.
Int J Cardiol; 2016 Jul 01; 214():209-15. PubMed ID: 27070994
[Abstract] [Full Text] [Related]
14. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
Wei M, Huang M, Chen S, Huang G, Huang M, Qiu D, Guo Z, Jiang J, Zhou X, Yu Q, Guo Y, Fu L, Gao W, Li F.
Pediatr Cardiol; 2015 Aug 01; 36(6):1166-72. PubMed ID: 25812827
[Abstract] [Full Text] [Related]
15. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
Berdej-Szczot E, Małecka-Tendera E, Gawlik T, Firek-Pędras M, Szydłowski L, Gawlik A.
Kardiol Pol; 2017 Aug 01; 75(3):261-266. PubMed ID: 27995598
[Abstract] [Full Text] [Related]
16. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R.
Paediatr Int Child Health; 2018 Aug 01; 38(3):209-212. PubMed ID: 29768976
[Abstract] [Full Text] [Related]
17. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
Takekoshi N, Kitano N, Takeuchi T, Suenaga T, Kakimoto N, Suzuki T, Kada TT, Shibuta S, Tachibana S, Murayama Y, Yamaga H, Suzuki H.
JAMA Netw Open; 2022 Jun 01; 5(6):e2216642. PubMed ID: 35696166
[Abstract] [Full Text] [Related]
18. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
Zhonghua Er Ke Za Zhi; 2006 Dec 01; 44(12):891-5. PubMed ID: 17254453
[Abstract] [Full Text] [Related]
19. Corticosteroids for the treatment of Kawasaki disease in children.
Wardle AJ, Connolly GM, Seager MJ, Tulloh RM.
Cochrane Database Syst Rev; 2017 Jan 27; 1(1):CD011188. PubMed ID: 28129459
[Abstract] [Full Text] [Related]
20. Kawasaki disease: a comprehensive review of treatment options.
Patel RM, Shulman ST.
J Clin Pharm Ther; 2015 Dec 27; 40(6):620-5. PubMed ID: 26547265
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
